Prostate Cancer Studies - PC-REF
Download
Report
Transcript Prostate Cancer Studies - PC-REF
Prostate Cancer Studies
Mohamed Bidair, M.D.
Diplomate, American Board of Urology
Alvarado La Mesa Urology
f Medical Associates
Prostate Cancer Research and Education
Foundation
Featured Speaker Series
December 13, 2003
Prostate Cancer Studies
An investigational selective endothelin
receptor antagonist, being developed for the
treatment of prostate cancer. These patients
must be status-post prostatectomy, hormone
naïve, with rising PSA.
Prostate Cancer Studies
Open-Label Leuprolide formulation for
patients with prostate cancer in need of
chemical castration. A percentage of
patients currently on a leuprolide castration
regime can be entered in the study if dosing
schedule isn’t interupted
Prostate Cancer Studies
A 3 Month Open Label study for patients
with advanced prostate cancer curently
receiving Lupron or Zoladex versus a new
investigational Leuprolide. The study is
looking to compare the degree of
testosterone suppression, Quality of Life
and safety and tolerability between Lupron,
Zoladex, and a new agent.
Prostate Cancer Studies
An intravenous bisphosphonate to study the
efficacy on the bone mineral density in
patients undergoing androgen deprivation
therapy for < 1 year. No distant metastasis
is required to enter study.
Prostate Cancer Studies
A new oral bisphosphonate to prevent
skeletal complications in metatastic prostate
cancer patients commencing androgen
deprivation therapy.
Prostate Cancer Studies
A new investigational drug, a SERM, to
prevent androgen deprivation induced
osteoporosis. This compund may also have
a direct inhibitory effect on cancer cells, and
ameliorate gynecomastia and hot flashes.
These patients must have received LHRH
treatment > 2 years, PSA < 4, and do not
take anti-androgens (Casodex, Eulexin)
Prostate Cancer Studies
An agent being evaluated to reduce the need
for transfusion in anemic patients with nonmyeloid cancer who are not receiving
chemotherapy or radiotherapy.
Prostate Cancer
Prevention Study
A study to assess the efficacy and safety of AlphaReductase Inhibitor. A 4 year study to reduce the
risk of biopsy detectable prostate cancer. Looking
for males 50-75 with only one negative biopsy
within 6 months of study enrollment. PSA must
be between 2.5-10 for males ages 50-60 and
between 3-10 for men > 60 years. Must not have
had more than one prostate biopsy or any other
prostate surgical procedures.